Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progesterone receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    266 result(s) found for: Progesterone receptor. Displaying page 9 of 14.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2017-002930-22 Sponsor Protocol Number: IOM-050371 Start Date*: 2018-02-14
    Sponsor Name:iOMEDICO AG
    Full Title: A randomized, open-label, multicenter, two-arm, phase III study to evaluate efficacy and quality of life in patients with metastatic hormone receptor-positive HER2-negative breast cancer receiving ...
    Medical condition: The study will include adult women with HR-positive, HER2-negative advanced breast cancer with visceral metastases, who received no prior therapy for advanced disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003600-12 Sponsor Protocol Number: MORAb-202-G000-201 Start Date*: 2022-07-25
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Sele...
    Medical condition: Solid tumors expressing folate receptor alpha in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer aden...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002437-21 Sponsor Protocol Number: GEICAM/2014-12 Start Date*: 2015-11-09
    Sponsor Name:GEICAM (Spanish Breast Cancer Research Group Foundation)
    Full Title: A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in...
    Medical condition: Postmenopausal women presenting with HR-positive/HER2-negative metastatic breast cancer who have received at least 5 years of endocrine therapy in the adjuvant setting as treatment for early diseas...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003402-46 Sponsor Protocol Number: CAN04CLIN005 Start Date*: 2021-09-23
    Sponsor Name:Cantargia AB
    Full Title: A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. “TRIFOUR study”.
    Medical condition: Unresectable locally advanced or metastatic triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022968-13 Sponsor Protocol Number: ET-B-031-10 Start Date*: 2011-03-16
    Sponsor Name:Pharma Mar, S.A. Sociedad Unipersonal
    Full Title: Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderm...
    Medical condition: Advanced Breast Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004225-14 Sponsor Protocol Number: PQR309-007 Start Date*: 2016-01-19
    Sponsor Name:PIQUR Therapeutics AG
    Full Title: An open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and tr...
    Medical condition: Locally advanced or metastatic HER2 negative and triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    18.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003507-35 Sponsor Protocol Number: AV-951-12-204 Start Date*: 2013-05-20
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in t...
    Medical condition: Locally recurrent and/or metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006193 Breast cancer NOS recurrent LLT
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000113-20 Sponsor Protocol Number: ABI-007-MBC-001 Start Date*: 2013-07-23
    Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
    Full Title: A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUB...
    Medical condition: ER, PgR, and HER2 negative (triple negative) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10006289 Benign and malignant breast neoplasms HLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Prematurely Ended) GR (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005275-15 Sponsor Protocol Number: 20050209 Start Date*: 2006-07-11
    Sponsor Name:Amgen Limited
    Full Title: A Randomized, Double- Blind, Placebo- Controlled, Multi- Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects with Non- Metastatic Breast Cancer Receiving Aromatase Inhib...
    Medical condition: Early non-metastatic breast cancer and therapy-induced bone loss and fractures
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10065687 Bone loss PT
    21.1 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005119-42 Sponsor Protocol Number: MO39193 Start Date*: 2018-01-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOC...
    Medical condition: Triple-Negative Breast Cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Completed) FI (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003319-12 Sponsor Protocol Number: ICR-CTSU-2014-10046 Start Date*: 2015-03-27
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Insitute of Cancer Research
    Full Title: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003126-25 Sponsor Protocol Number: MS201923-0001 Start Date*: 2012-09-27
    Sponsor Name:Merck KGaA
    Full Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
    Medical condition: cancer (malignant solid tumors)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005834-19 Sponsor Protocol Number: GBG44 Start Date*: 2007-10-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer
    Medical condition: breast cancer, primary systemic therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019965-27 Sponsor Protocol Number: SAKK21/08 Start Date*: 2011-03-25
    Sponsor Name:Swiss Group for Clinical Cancer Research
    Full Title: Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: a randomized placebo-contr...
    Medical condition: Patient with advanced stage breast cancer (HER2 positive is allowed), i.e. locally advanced or metastatic breast cancer that is not amenable to curative surgery and/or radiation.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004310-33 Sponsor Protocol Number: CAR4SAR Start Date*: 2022-02-21
    Sponsor Name:Dr. Antonio Pérez Martínez
    Full Title: A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma
    Medical condition: Advanced Sarcoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001984-11 Sponsor Protocol Number: FM-14-B01 Start Date*: 2014-12-22
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E DELLA CURA DEI TUMORI
    Full Title: “Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment “
    Medical condition: Women with a diagnosis of invasive unilateral non metastatic HER2-positive and ER-positive breast cancer suitable for neoadjuvant therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10006283 Breast neoplasm malignant female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006458-91 Sponsor Protocol Number: KU36-44 Start Date*: 2007-05-22
    Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies)
    Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat...
    Medical condition: Advanced breast cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Ongoing) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001438-16 Sponsor Protocol Number: OBI-822-011 Start Date*: 2022-01-25
    Sponsor Name:OBI Pharma, Inc.
    Full Title: The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004637-20 Sponsor Protocol Number: D361DC00001 Start Date*: 2021-07-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase Ib/III Randomised Study of Capivasertib plus CDK4/6i and Fulvestrant versus Placebo plus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Rec...
    Medical condition: Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 08:34:29 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA